iTeos Therapeutics, Inc.

iTeos Therapeutics, Inc.verified

ITOS

Price:

$7.35

Market Cap:

$268.52M

Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachuset...[Read more]

Industry

Biotechnology

IPO Date

2020-07-24

Stock Exchange

NASDAQ

Ticker

ITOS

The Enterprise Value as of December 2024 (TTM) for iTeos Therapeutics, Inc. (ITOS) is 150.31M

According to iTeos Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 150.31M. This represents a change of -48.04% compared to the average of 289.28M of the last 4 quarters.

iTeos Therapeutics, Inc. (ITOS) Historical Enterprise Value (quarterly & annually)

How has ITOS Enterprise Value performed in the past?

The mean historical Enterprise Value of iTeos Therapeutics, Inc. over the last ten years is 497.43M. The current 150.31M Enterprise Value has changed 2.92% with respect to the historical average. Over the past ten years (40 quarters), ITOS's Enterprise Value was at its highest in in the March 2021 quarter at 867.80M. The Enterprise Value was at its lowest in in the September 2022 quarter at -30406153.00.

Quarterly (TTM)
Annual

Average

497.43M

Median

533.46M

Minimum

127.42M

Maximum

848.89M

iTeos Therapeutics, Inc. (ITOS) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of iTeos Therapeutics, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 412.27%

Maximum Annual Enterprise Value = 848.89M

Minimum Annual Increase = -64.63%

Minimum Annual Enterprise Value = 127.42M

Quarterly (TTM)
Annual
YearEnterprise ValueChange
2023146.49M-64.63%
2022414.20M-47.89%
2021794.85M-6.37%
2020848.89M30.05%
2019652.72M412.27%

iTeos Therapeutics, Inc. (ITOS) Average Enterprise Value

How has ITOS Enterprise Value performed in the past?

The current Enterprise Value of iTeos Therapeutics, Inc. (ITOS) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

3-year avg

451.85M

5-year avg

571.43M

10-year avg

497.43M

iTeos Therapeutics, Inc. (ITOS) Enterprise Value vs. Peers

How is ITOS’s Enterprise Value compared to its peers?

iTeos Therapeutics, Inc.’s Enterprise Value is less than Icosavax, Inc. (713.87M), less than Mirati Therapeutics, Inc. (3.91B), less than VectivBio Holding AG (848.58M), less than Annexon, Inc. (512.88M), less than Gracell Biotechnologies Inc. (5.66B), greater than Theseus Pharmaceuticals, Inc. (138.26M), less than Monte Rosa Therapeutics, Inc. (356.78M), less than Design Therapeutics, Inc. (323.81M), less than Erasca, Inc. (685.22M), less than Apellis Pharmaceuticals, Inc. (4.20B), greater than TScan Therapeutics, Inc. (117.88M), less than Terns Pharmaceuticals, Inc. (234.86M), less than Day One Biopharmaceuticals, Inc. (859.59M), greater than Acumen Pharmaceuticals, Inc. (103.15M), less than Amylyx Pharmaceuticals, Inc. (209.72M), less than MoonLake Immunotherapeutics (2.92B), less than Revolution Medicines, Inc. (7.90B), less than Blueprint Medicines Corporation (6.12B), less than Sana Biotechnology, Inc. (333.02M), less than Kymera Therapeutics, Inc. (2.62B),

Build a custom stock screener for iTeos Therapeutics, Inc. (ITOS) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like iTeos Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

iTeos Therapeutics, Inc. (ITOS) and other stocks custom spreadsheet templates

The easiest way to analyze a company like iTeos Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the Enterprise Value?

How can you use the Enterprise Value?

What is iTeos Therapeutics, Inc.'s Enterprise Value?

What is the highest Enterprise Value for iTeos Therapeutics, Inc. (ITOS)?

What is the 3-year average Enterprise Value for iTeos Therapeutics, Inc. (ITOS)?

What is the 5-year average Enterprise Value for iTeos Therapeutics, Inc. (ITOS)?

How does the current Enterprise Value for iTeos Therapeutics, Inc. (ITOS) compare to its historical average?